DPS Engineering, which specialises in designing, validation, and project management services to the pharmaceutical industry, says it will be creating 250 new jobs, as part of its further expansion into Europe.
The company said yesterday that many of the new jobs will be for third level graduates, and will be created over the next five years.
The company, which has offices in Cork, Dublin and Leiden in Holland, has turnover of around 20 million, and has been expanding rapidly since the mid-1990s when it had just 25 employees in its Cork offices.
Michael Mulhall, DPS Engineering’s chairman said the company was targeting further expansion in continental Europe over the next five years.
Already around 30% of the company’s business comes from Europe, and Mr Mulhall is forecasting that the company will grow by 15% a year.
DPS counts some of the world’s biggest drug and biotech companies, including Roche and Pfizer, among its clients, and Mulhall said Ireland has the potential to benefit from the growth in the pharmaceutical sector.
“A tremendous opportunity exists for Ireland Inc in biopharmaceuticals.
“New plants will be needed, we are very much at ease in Ireland with the technologies involved, we have a supportive third level education sector, and a workforce with world class skills,” he said.
“The portents are very good for Ireland Inc in this regard, and obviously, we at DPS Engineering, are extremely confident of continuing the strong and rapid growth we have achieved to date,” Mulhall said.
He said that the pharmaceutical sector accounts for around 30% of Irish economic growth, and is a major employer, with 16,000 jobs in the sector.
Mulhall believes Ireland can extend leadership in the sector if investment continues.
“The IDA had done a tremendous job in creating the climate in which the sector could thrive, and third-level educational institutions have been tremendously responsive in meeting the evolving requirement of the sector,” he said.
Mulhall welcomed the establishment of the School of Pharmacy and Bioscience at UCC, saying it will add to Ireland’s attractiveness as a destination for pharmaceutical investment.
He added that “Ireland was now a global centre of excellence for the pharmaceutical industry,” and was now “exporting world class specialist skills in design, construction, and validation of major pharmaceutical projects.”
The company also opened its new offices in Cork over the weekend.